Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Jiunn Tyng Yeh"'
Autor:
Jiunn-Tyng Yeh, Boaz Shulruf, Hsin-Chen Lee, Pin-Hsiang Huang, Wen-Hua Kuo, Tyzh-Chang Hwang, Chen-Huan Chen
Publikováno v:
BMC Medical Education, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background A rigorous faculty appointment and promotion (FAP) system is vital for the success of any academic institution. However, studies examining the FAP system in Asian universities are lacking. We surveyed the FAP policies of Taiwan’
Externí odkaz:
https://doaj.org/article/353b33d6e85449748044a0dae8b4c836
Autor:
Tzu‐Jung Chiu, Jiunn‐Tyng Yeh, Chi‐Jung Huang, Chern‐En Chiang, Shih‐Hsien Sung, Chen‐Huan Chen, Hao‐Min Cheng
Publikováno v:
The Journal of Clinical Hypertension, Vol 23, Iss 8, Pp 1463-1482 (2021)
Abstract The variability of blood pressure (BPV) has been suggested as a clinical indicator for cognitive dysfunction, yet the results from clinical studies are variable. This study investigated the relationship between BPV and the risk of cognitive
Externí odkaz:
https://doaj.org/article/a5e2526d3848430c9143b9c86a8a2b70
Publikováno v:
Frontiers in Molecular Biosciences, Vol 9 (2022)
Cystic fibrosis (CF) is a lethal hereditary disease caused by loss-of-function mutations of the chloride channel cystic fibrosis transmembrane conductance regulator (CFTR). With the development of small-molecule CFTR modulators, including correctors
Externí odkaz:
https://doaj.org/article/4e430ee905ab43e39072ecb308e8adb4
Autor:
Winnie Khor, Tzyh-Chang Hwang, Chih-Chien Wang, Aliaksandr A. Yarmishyn, Jiunn-Tyng Yeh, Shih-Hwa Chiou, Shih-Jie Chou
Publikováno v:
Stem Cell Research, Vol 60, Iss , Pp 102683- (2022)
Cystic fibrosis (CF) is a genetic disease affects CFTR channel synthesis. While 90 percent of the CF patients now benefit from small molecule target therapies, this treatment has yet to extend to those bearing nonsense mutations. Studies of these rar
Externí odkaz:
https://doaj.org/article/d320ba5238754044b926d5f68138bc5b
Publikováno v:
The Journal of Clinical Hypertension, Vol 24, Iss 1, Pp 89-90 (2022)
Externí odkaz:
https://doaj.org/article/93136af2ee4a4817b2377ab70d6f892f
Publikováno v:
The Journal of Clinical Hypertension, Vol 23, Iss 10, Pp 1943-1944 (2021)
Externí odkaz:
https://doaj.org/article/80b8b8ba128c4c7f97f4493d59d024d0
Autor:
Kun-Han Lee, Ying-Fan Chen, Wan-Yu Yeh, Jiunn-Tyng Yeh, Tzu-Han Yang, Chian-Ying Chou, Yuh-Lih Chang, Wei-Ting Wang, Chern-En Chiang, Chen-Huan Chen, Hao-Min Cheng
Publikováno v:
Age and Ageing. 51
Background An optimal antithrombotic strategy for patients aged 80 years or older with atrial fibrillation (AF) remains elusive. Objective Using a systematic review with traditional and network meta-analysis, we investigated outcomes in AF patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9052bd5f45fcb618779d60f430bed670
https://doi.org/10.1093/ageing/afac292
https://doi.org/10.1093/ageing/afac292
Publikováno v:
PLoS ONE, Vol 13, Iss 12, p e0209862 (2018)
Cystic fibrosis transmembrane conductance regulator (CFTR), the culprit behind the genetic disease cystic fibrosis (CF), is a phosphorylation-activated, but ATP-gated anion channel. Studies of human CFTR over the past two decades have provided an in-
Externí odkaz:
https://doaj.org/article/e6c4c1118f51469ba91e3b394fc2e79b
Autor:
Jiunn-Tyng Yeh, Chun-Wei Lee, Yu-Jen Chen, Shao-Li Huang, Wei-Ting Wang, Chi-Jung Huang, Tzu-Jung Chiu, Chen-Huan Chen, Chern-En Chiang, Hao-Min Cheng
Publikováno v:
Journal of Hypertension. 40:e87-e88
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f279ee96c68b89c2d6d529540b6001ce
https://doi.org/10.1097/01.hjh.0000836064.12341.81
https://doi.org/10.1097/01.hjh.0000836064.12341.81
Autor:
Winnie Khor, Tzyh-Chang Hwang, Chih-Chien Wang, Aliaksandr A. Yarmishyn, Jiunn-Tyng Yeh, Shih-Hwa Chiou, Shih-Jie Chou
Publikováno v:
Stem Cell Research, Vol 60, Iss, Pp 102683-(2022)
Cystic fibrosis (CF) is a genetic disease affects CFTR channel synthesis. While 90 percent of the CF patients now benefit from small molecule target therapies, this treatment has yet to extend to those bearing nonsense mutations. Studies of these rar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a00dee303d2d0b037adc39a9aa107925
https://pubmed.ncbi.nlm.nih.gov/35091309
https://pubmed.ncbi.nlm.nih.gov/35091309